When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Danuglipron - Wikipedia

   en.wikipedia.org/wiki/Danuglipron

   Danuglipron is a small-molecule GLP-1 agonist developed by Pfizer [1] that, in an oral formulation, is under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicate that it reduced weight [2] and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and ...

3. This Promising Weight Loss Drug Candidate Could Be a Huge ...

   www.aol.com/promising-weight-loss-drug-candidate...

   The GLP-1 agonist market could be worth around $100 billion according to some estimates. If Pfizer can become a big player in it, that could be just the catalyst that the business needs.

4. Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't ...

   www.aol.com/pfizer-buy-glp-1-drugmaker-082000648...

   For premium support please call: 800-290-4726 more ways to reach us

5. Pfizer's twice-daily weight-loss pill discontinued due to ...

   www.aol.com/ozempic-without-injection-weight...

   Pfizer is also testing another oral GLP-1 drug called lotiglipron, which would be taken once a day. It’s currently at the phase 2 trial stage, according to the company’s drug pipeline ...

6. Lotiglipron - Wikipedia

   en.wikipedia.org/wiki/Lotiglipron

   Lotiglipron is a non-peptide glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Pfizer. [1] It was withdrawn from development after early stage clinical trials showed elevated liver enzymes which could indicate potential for liver toxicity. [2]

7. Pfizer moves forward with once-daily weight-loss pill - AOL

   www.aol.com/news/pfizer-moves-forward-once-daily...

   (Reuters) -Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice ...